Brain+ (BRAINP) Investor Update summary

Market and product strategy

• Launched a scalable digital dementia care platform, Ayla, targeting both NHS and care home sectors in the U.K. and using Denmark as a test market.

• Ayla addresses inefficiencies in current CST delivery, offering digital, standardized, and compliant solutions to reduce wait times and improve access.

• Accredited as a CST trainer with UCL, enabling integration into CST education and global expansion opportunities.

• Hyper-targeted, data-driven sales approach with RAG-rated NHS pipeline and strong care home sector engagement.

• Diversified revenue streams from NHS, care homes, and direct-to-professional channels.

Financial outlook and guidance

• Conservative SaaS-based financial model projects ARR of €1M by end-2025 and €3.8M by end-2027, with break-even in U.K. operations by end-2025 and company-wide by end-2026.

• Targeting 218 active sites by 2027, with a total addressable U.K. market ARR potential of €50–75M by 2032.

• Danish market provides pilot and validation value, but main revenue focus is on the U.K.

• Funding strategy includes a bridge round in Q4 and a larger growth round in Q2 2025, aiming to minimize shareholder dilution.

Commercial progress and milestones

• Achieved rapid U.K. market entry, rebranding, and product launch within eight weeks, with strong early traction in care homes and NHS leads.

• Secured new and renewed contracts in Denmark, with multi-year and expanded site opportunities.

• Appointed a key U.K. care home MD as advisor, strengthening sector access.

• Applying to an Alzheimer's Society accelerator for further market access.